Gün + Partners
Practitioners reveal how changes to non-use cancellations, first outlined in 2017 but yet to be formalised, are affecting their strategies
Sponsored
Sponsored
-
Sponsored by Gün + PartnersSelin Sinem Erciyas and Aysel Korkmaz Yatkın of Gün + Partners explain the significance of a ruling in Turkey on the validity of second medical use patents granted by the European Patent Office -
Sponsored by Gün + PartnersZeynep Seda Alhas and Dilan Sıla Kayalıca of Gün + Partners consider the Turkish IP office’s ruling on the opposition proceedings initiated by TBL Licensing, the owner of the Timberland trademark
-
Sponsored by Gün + PartnersSelin Sinem Erciyas of Gün + Partners suggests that intellectual property waivers and compulsory licensing are not the answer in developing and accessing vaccines, and explains why governments should be focused on R&D
-
Sponsored by Gün + PartnersBarış Kalaycı and Direnç Bada of Gün and Partners discuss an IP case that led to the discovery, and removal, of fake fire-resistant glass from hospitals in Turkey
-
Sponsored by Gün + PartnersAysel Korkmaz Yatkın and Fatma Sevde Tan of Gün and Partners discuss a welcome decision that reinforces patent owners’ right to information about pharmaceutical licensing applications in Turkey
-
Sponsored by Gün + PartnersÖzge Atılgan Karakulak and Beste Turan of Gün + Partners consider how technological advancement supports the creation of SEPs in Turkey
